撰文丨王聪 编辑丨王多鱼 排版丨水成文 嵌合抗原受体 （CAR） -T 细胞疗法，已经彻底改变了血液系统恶性肿瘤患者的治疗格局，但其应用仍受限于劳动密集型的制造流程、有限的生产能力以及不稳 定的临床疗效。 体内 CAR-T （ in vivo CAR-T） 细胞工程技术，通过直接在患者体内生成 CAR-T 细胞，消除了体外细胞处理和复杂物流的需求，同时提升临床疗效，力求克 服上述挑战。 病毒学、RNA 药物和纳米技术的最新进展促使 in vivo CAR-T 发生了根本性变革，通过慢病毒载体和脂质纳米颗粒 （LNP） 等靶向递送系统，将编码 CAR 的 遗传物质导入内源性 T 细胞。早期临床研究已证实了高效转导、持续 CAR 表达和抗肿瘤活性的早期迹象，完成了概念验证。 近日，CAR-T 细胞治疗先驱 Carl June ， 诺奖得主、mRNA 技术先驱 Drew Weissman ， 以及 Capstan、 Umoja、 Kelonia、 Moderna、 Myeloid、 Interius、 Orna、 Sana、 Carisma 等细胞疗法和 mRNA 技术公司的研究人员，在 Nature 旗下综述期刊 ...

NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that in connection with the Company’s transition to a fully integrated commercial organization it has appointed James M. O’Brien as its US-based Chief Financial Officer (CFO). Jim has extensive experience in all aspects of financial management and planning having spent the majority of his career with multi-national public and private ...

回顾：上周6只新股上市，共募资约5.4亿美元。 Off The Hook(OTH)以每股4美元，发行了375万股(原计划发行500万股)，募集了1500万美元。 Phaos Technology(POAS)以每股4美元，发行了360万股，募集了1440万美元。 Caring Brands(CABR)以每股4美元，发行了100万股，募集了400万美元。 SPAC Evolution Global Acquisition (EVOXU)、Blueport Acquisition (BPACU)、Alussa Energy Acquisition II (ALUBU)分别募集了2.1亿美元、5000万美元、2.5 亿美元。 此外，12家公司递交招股书，其中5家来自中国，含4家空白招股书(拟通过这种方式上市毫无可能)，另1家为客路(KLK)，详情请见：IPO速递丨客路赴美 IPO 拟纽交所上市 红杉、软银为股东 本周，暂有4家公司计划上市，如下： 1、专注于信仰的技术平台——Gloo Holdings, Inc. 股票代码：GLOO Gloo为信仰组织提供垂直一体化平台服务的公司，主要提供涵盖云服务、IT管理、网络安 ...

The after-hours session on Friday, November 14, 2025, brought notable moves across several biotech and therapeutics names, as corporate updates, financial results, and strategic announcements drove sharp price reactions. From acquisition agreements to pivotal trial milestones, these developments shaped trading momentum well beyond the regular market close.Repare Therapeutics Inc. (RPTX) surged in after-hours trading, closing at $2.15, up 30.32% or $0.50. The company announced that it has entered into a def ...

NEW YORK, Nov. 16, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Jasper Therapeutics, Inc. (NASDAQ: JSPR) between November 30, 2023 and July 3, 2025, both dates inclusive (the “Class Period”), of the important November 18, 2025 lead plaintiff deadline. SO WHAT: If you purchased Jasper Therapeutics securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingen ...

UroGen Pharma Ltd. (NASDAQ:URGN) is one of the best small-cap biotech stocks to buy according to analysts. UroGen Pharma (URGN) Closes Q3 2025 With $127.4 Million in Cash Amid Rising R&D Costs On November 6, 2025, UroGen Pharma Ltd. (NASDAQ:URGN) reported its Q3 2025 results, highlighting strong growth in demand alongside its steady commercial expansion. Furthermore, preliminary October figures indicated that demand revenue more than doubled compared to the previous three months. This growth reflects the ...

With significant upside potential, Liquidia Corporation (NASDAQ:LQDA) secures a spot on our list of the best small-cap biotech stocks to buy according to analysts. Raymond James Remains Bullish on Liquidia (LQDA), Cites YUTREPIA’s 75% Growth in U.S. Prostacyclin Revenue On November 4, 2025, Raymond James raised its price target on Liquidia Corporation (NASDAQ:LQDA) from $41 to $47, while reiterating a “Strong Buy” rating. The investment firm’s bullish stance reflects YUTREPIA’s 75% growth in U.S. prostac ...

Biohaven Ltd. (NYSE:BHVN) is one of the best small-cap biotech stocks to buy according to analysts. William Blair Maintains Bullish Stance on Biohaven (BHVN), Sees Robust Operational Growth On November 11, 2025, William Blair kept its “Market Perform” rating. The investment firm sees the FDA’s Complete Response Letter (CRL) for Vyglxia as a key driver for pipeline reprioritization. The firm also cited the company’s projection of a 60% reduction in direct spend on non-priority assets. William Blair believ ...

JSPR DEADLINE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Jasper Therapeutics, Inc. Investors to Secure Counsel Before Important November 18 Deadline in Securities Class Action - JSPRNovember 16, 2025 9:38 PM EST | Source: The Rosen Law Firm PANew York, New York--(Newsfile Corp. - November 16, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Jasper Therapeutics, Inc. (NASDAQ: JSPR) between November 30, 2023 and July 3, 2025, both dates inclusiv ...

公司治理与股权变更 - 股东特别会议所有提案均获多数票通过 [1] - Faraday Future成为公司新的控股股东，直接持股约55%，连同关联股东YT Jia和Jerry Wang，总持股比例增至约63% [2] - Faraday Future将任命重组后董事会的大部分成员，治理结构调整将于公司计划更名前完成 [3] 战略转型与品牌重塑 - 公司将于2025年11月20日正式更名为AIxCrypto Holdings, Inc，并在纳斯达克举行更名及代码激活仪式，新交易代码为AIXC [4][10] - 此次品牌演变标志着公司从传统生物技术向Web3驱动的去中心化人工智能技术平台的战略转型 [5] - 更名象征着公司身份、商业模式、技术战略和生态系统定位的全面升级，公司明确转型为专注于去中心化AI、Web3资产基础设施和智能交易系统的跨学科技术企业 [6][8] 未来发展蓝图与活动 - 在11月20日的仪式上，公司将公布全新的业务框架、生态系统架构以及三年发展路线图，旨在将自身定位为AI × Web3时代的全球领先门户 [4][7][10] - 此次转型预计将在AIxCrypto与Faraday Future之间建立互惠的战略赋能动态，加速创新、生态系统整合和长期价值创造 [5] - 公司将进入与其技术、增长和资本市场战略相一致的新执行阶段 [12] 股东会议批准事项 - 根据纳斯达克规则5635(a)和(b)批准了认购协议，授权发行337,432股普通股和39,943股B系列可转换优先股 [11] - 批准根据规则5635(d)超过纳斯达克19.99%的发行门槛 [11] - 批准包含常青条款的2025年股权激励计划，以支持长期人才保留并与股东利益保持一致 [11]